For the Inventor, By the Inventor

Enter assignee name

Cranbury, NJ, United States of America

Palatin Technologies Incorporated

USPTO Granted Patents = 67

CIPO Patents = 15

EPO Patents = 8

Trademarks = 5

Forward Citations = 435

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Shubh D Sharma (47 out of 61 patents)

Yi-Qun Shi (36 out of 36 patents)

Wei Yang (31 out of 31 patents)

4. Ramesh Rajpurohit (19 out of 19 patents)

5. Annette M Shadiack (14 out of 19 patents)

6. Zhijun Wu (13 out of 13 patents)

7. Kevin D Burris (10 out of 10 patents)

8. Margarita Bastos (9 out of 14 patents)

9. Hui-Zhi Cai (9 out of 9 patents)

10. John H Dodd (7 out of 8 patents)

11. Papireddy Purma (7 out of 7 patents)

12. Carl Spana (5 out of 5 patents)

13. Xin Chen (5 out of 5 patents)

14. Jeffrey D Edelson (4 out of 4 patents)

15. Yadi Reddy Bonuga (4 out of 4 patents)

Core Competencies:

Melanocortin Receptor

Bremelanotide

Peptide Constructs

Cyclic Peptides

Sexual Dysfunction

Obesity Therapies

Diabetes Treatments

Cytokine Storm Therapy

Peptidomimetics

Natriuretic Peptides

Inflammation Therapy

Piperazine Compounds

67 patents: Sort by Forward Citations

1. 12459894 - Orally active melanocortin receptor-4 compounds (2025-11-04),

2. 11590209 - Use of bremelanotide in patients with controlled hypertension (2023-02-28),

3. 11286280 - Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy (2022-03-29),

4. 10711039 - Melanocortin receptor-specific peptide with C-terminal naphthylalanine (2020-07-14),

5. 10660939 - Therapies for obesity, diabetes and related indications (2020-05-26),

6. 10632171 - Melanocortin receptor-specific peptides (2020-04-28),

7. 10286034 - Uses of bremelanotide in therapy for female sexual dysfunction (2019-05-14),

8. 10179804 - Melanocortin receptor-specific peptides (2019-01-15),

9. 10106578 - Melanocortin-1 receptor-specific linear peptides (2018-10-23),

10. 10017539 - Melanocortin-1 receptor-specific cyclic hexapeptides (2018-07-10),

11. 9700592 - Uses of bremelanotide in therapy for female sexual dysfunction (2017-07-11),

12. 9580466 - Melanocortin-1 receptor-specific linear peptides (2017-02-28),

13. 9458201 - Melanocortin receptor-specific heptapeptides (2016-10-04),

14. 9447148 - Melanocortin-1 receptor-specific cyclic peptides (2016-09-20),

15. 9352013 - Uses of bremelanotide in therapy for female sexual dysfunction (2016-05-31),

Palatin Technologies Incorporated is a biopharmaceutical company that specializes in the development of proprietary peptide therapeutics. Their focus is on discovering, developing, and commercializing innovative medicines to address unmet medical needs. With a strong pipeline of drug candidates, Palatin aims to provide safe and effective treatment options for patients in areas like sexual dysfunction and cardiovascular diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

67 Patents

#2 in Cranbury, NJ

#226 in New Jersey

#5,216 in US

#10,583 in the World

Cranbury, NJ, United States of America

Palatin Technologies Incorporated

Forward Citations = 435

37 inventors:

Shubh D Sharma (47 out of 61 patents)

Yi-Qun Shi (36 out of 36 patents)

Wei Yang (31 out of 31 patents)

4. Ramesh Rajpurohit (19 out of 19 patents)

5. Annette M Shadiack (14 out of 19 patents)

Please report any incorrect information to support@idiyas.com

Loading…